IP Library Patent Application 18474327
Patent Application
App. No. 18/474,327

Therapeutic Editing

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/474,327
Abstract

Disclosed herein are compositions that comprise engineered polynucleotides, pharmaceutical compositions comprising the same, methods of making the same, and methods of treatment comprising the compositions that comprise the engineered polynucleotides.

Claims (16)

1 . A composition that comprises: an engineered polynucleotide comprising a targeting sequence that is at least partially complementary to a region of a target RNA, wherein the region of the target RNA:

(a) comprises a sequence that at least partially encodes for an amyloid precursor protein (APP) polypeptide;

(b) comprises a sequence that is proximal to (a); or

(c) comprises (a) and (b); and wherein the engineered polynucleotide is configured to facilitate an editing of a base of a nucleotide of the target RNA by an RNA editing entity.

2 . The composition of claim 1 , wherein the editing of the base of the nucleotide of the target RNA by the RNA editing entity facilitates an increase or a decrease of:

(a) a processing;

(b) a cleavage; or

(c) (a) and (b),

of the APP polypeptide by a secretase enzyme, relative to an APP polypeptide encoded by the target RNA without the editing.

3 . The composition of claim 2 , wherein the secretase enzyme comprises: an alpha secretase; a beta secretase; a gamma secretase; or a combination thereof.

4 . The composition of claim 3 , wherein the secretase enzyme comprises the beta secretase, and wherein the beta secretase comprises beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), cathepsin B, or Meprin beta.

5 .- 32 . (canceled)

33 . The composition of claim 1 , wherein the nucleotide is comprised in a codon which encodes an amino acid in proximity to a cleavage site of the APP polypeptide, and wherein the amino acid is at position 670, 671, 672, 673, 682, 684, 687, 712, or 714 of the APP polypeptide comprising the polypeptide sequence of SEQ ID NO: 2.

34 .- 85 . (canceled)

86 . An engineered polynucleotide that comprises a sequence that comprises at least 90%, 95%, 97%, or 99% sequence identity with at least a portion of a sequence selected from: SEQ ID NO: 52, SEQ ID NO: 71-SEQ ID NO: 148, and SEQ ID NO: 159-SEQ ID NO: 167.

87 . An engineered polynucleotide that comprises a targeting sequence capable of at least partially binding to a sequence that comprises at least 90%, 95%, 97%, or 99% sequence identity with a portion of a sequence selected from: SEQ ID NO: 150-SEQ ID NO: 158 as determined by BLAST.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2023
From: HUSS, DAVID; MALI, PRASHANT; LAKSHMANAN, ANAUPAMA; NYE, CHRISTOPHER; SAVVA, YIANNIS; STEIN, LIANA; SULLIVAN, RICHARD; PONCE, RAFAEL
To: SHAPE THERAPEUTICS INC.
Reel/Frame 065023/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2023
From: BYRNE, SUSAN
To: SHAPE THERAPEUTICS INC.
Reel/Frame 065023/0917 →
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: SHAPE THERAPEUTICS INC.
To: SHAPE THERAPEUTICS INC.
Reel/Frame 065028/0050 →